Research progress of intestinal microbiota in targeted therapy and immunotherapy of colorectal cancer

被引:0
|
作者
Zhou, Xinying [1 ]
Zhao, Yu [1 ]
Zhao, Rongchuan [1 ]
Shafi, Shaheryar [1 ]
Yang, Yue [1 ]
Liu, Guangxing [1 ]
Liu, Song-Bai [2 ,3 ]
机构
[1] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Suzhou 215163, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Jiangsu Prov Engn Res Ctr Mol Target Therapy & Com, Suzhou 215009, Jiangsu, Peoples R China
[3] Suzhou Vocat Hlth Coll, Jiangsu Prov Engn Res Ctr Mol Target Therapy & Com, Kehua Rd 28, Suzhou 215009, Jiangsu, Peoples R China
关键词
CRC; gut microbiota; targeted therapy; immunotherapy; STREPTOCOCCUS-THERMOPHILUS; TUMOR-DEVELOPMENT; KAPPA-B; TUMORIGENESIS; CELLS; CARCINOGENESIS; PROLIFERATION; ANTIBACTERIAL; PROBIOTICS;
D O I
10.20517/2394-4722.2023.178
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract, with increasing morbidity and mortality worldwide, and is the third most common malignancy in the world. At present, the main treatment methods for CRC include surgery, chemotherapy, targeted therapy, and immunotherapy. Regulation of the gut microbiota is one of the most promising new strategies for CRC treatment. Gut microbiota interacts with host cells to regulate many physiological processes, such as energy acquisition, metabolism, and immune responses. Recent studies have found that a combination of gut microbiota with targeted therapy and immunotherapy could improve the therapeutic effect of colon cancer compared with treatment alone. This article reviews the mechanism of microbiota regulation in CRC and the latest progress of intestinal microbiota in targeted therapy and immunotherapy of CRC, which is helpful in developing potential prevention or treatment strategies for colorectal cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Research progress in targeted therapy and immunotherapy for gastric cancer
    Li Xuewei
    Xu Jun
    Xie Jun
    Yang Wenhui
    中华医学杂志英文版, 2022, 135 (11) : 1299 - 1313
  • [2] Research progress in targeted therapy and immunotherapy for gastric cancer
    Li, Xuewei
    Xu, Jun
    Xie, Jun
    Yang, Wenhui
    CHINESE MEDICAL JOURNAL, 2022, 135 (11) : 1299 - 1313
  • [3] Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer
    Azimi, Maryam
    Shahbaz, Sanaz Keshavarz
    Mansourabadi, Amir Hossein
    Khosroshahi, Leila Mohamed
    Pourkalhor, Shahryar
    Rezakhani, Mehran
    Masoumi, Farimah
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2022, 183 (11) : 1147 - 1165
  • [4] Current Progress in Targeted Therapy for Colorectal Cancer
    Ortega, Jose
    Vigil, Carlos E.
    Chodkiewicz, Catherine
    CANCER CONTROL, 2010, 17 (01) : 7 - 15
  • [5] Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
    Underwood, Patrick W.
    Ruff, Samantha M.
    Pawlik, Timothy M.
    CELLS, 2024, 13 (03)
  • [6] Advancements in combining targeted therapy and immunotherapy for colorectal cancer
    Singh, Manisha
    Morris, Van Karlyle
    Bandey, Irfan N.
    Hong, David S.
    Kopetz, Scott
    TRENDS IN CANCER, 2024, 10 (07) : 598 - 609
  • [7] Intestinal microbiota and colorectal cancer: a new aspect of research
    Koliarakis, Ioannis
    Psaroulaki, Anna
    Nikolouzakis, Taxiarchis Konstantinos
    Kokkinakis, Manolis
    Sgantzos, Markos N.
    Goulielmos, George
    Androutsopoulos, Vasilis P.
    Tsatsakis, Aristides
    Tsiaoussis, John
    JOURNAL OF BUON, 2018, 23 (05): : 1216 - 1234
  • [8] Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
    Xie, Shuqi
    Wang, Mengchao
    Zeng, Chuanxiu
    Ou, Yan
    Zhao, Lu
    Wang, Dong
    Chen, Liwei
    Kong, Fanming
    Yi, Dan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Progress of research on molecular targeted therapies for colorectal cancer
    Huang, Shilin
    Ye, Jiazhou
    Gao, Xing
    Huang, Xi
    Huang, Julu
    Lu, Lu
    Lu, Cheng
    Li, Yongqiang
    Luo, Min
    Xie, Mingzhi
    Lin, Yan
    Liang, Rong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
    Zhang, Bo
    Fang, Chenyan
    Deng, Dehou
    Xia, Liang
    ONCOLOGY LETTERS, 2018, 16 (01) : 27 - 33